LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients

By sjmartinez • July 5, 2022

Altinbas A, Holmes JA, Salloum S, Lidofsky A, Alatrakchi N, Somsouk M, Hunt P, Deeks S, Chew KW, Lauer G, Kruger A, Lin W, Chung RT. LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. Biomark Med. 2022 Aug;16(11):839-846. doi: 10.2217/bmm-2021-0596. Epub 2022 Jul 5. PMID: 35786977.

Tags: antiretroviral therapy, hepatitis C virus infection, HIV infection, Infectious Diseases, liver fibrosis, LOXL-2, peginterferon and ribavirin therapy, Publications, TNC-C

A Tale of Two Islands – Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights

Haake DA. A Tale of Two Islands - Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights. Am J Trop Med Hyg. 2024 May 2:tpmd240254.[...]

Contribution of syphilis to adverse pregnancy outcomes in people living with and without HIV in south Brazil: 2008-2018

Yang LZ, Sundar KG, Cambou MC, Swayze EJ, Segura ER, Gonçalves de Melo M, Santos BR, Rosângela Dos Santos Varella I, Nielsen-Saines K. Contribution of[...]

Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission

Njuguna I, Saidi F, Joseph Davey D, Chi BH, Pintye J. Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission. Front[...]